Norton, Massachusetts — According to state and local development sources, Alnylam Pharmaceuticals plans to invest $250 Million to expand in Norton. The company plans to occupy the new space at 20 Commerce Way in Norton, on or about October 1, 2027. According to the company website Alnylam Pharmaceuticals is a leading biopharmaceutical company dedicated to pioneering RNA interference (RNAi) therapeutics, an innovative class of medicines designed to treat diseases by silencing the genes that cause or contribute to them. Driven by science and inspired by patients, Alnylam focuses on developing RNAi-based medicines for both rare and prevalent diseases across various therapeutic areas. The company is committed to corporate responsibility, aiming to have a positive impact beyond its medicines, and has been recognized as a “Best Workplace for Innovators” for five consecutive years. Alnylam recently announced its 2030 Strategy and a significant expansion of its U.S. manufacturing facility, demonstrating its ongoing growth and commitment to advancing RNAi therapeutics.

To learn more about Alnylam Pharmaceuticals, visit https://www.alnylam.com/

Company Contact:
Yvonne Greenstreet, Chief Executive Officer
877-256-9526

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.